Dingxiao Zhang

This study quantifies cancer stemness in prostate cancer across progression stages, showing its association with therapy resistance, poor survival, and lineage plasticity.

This study identifies VARS1 as a driver of prostate cancer progression by altering codon usage in translation, showing that targeting VARS1 can suppress tumor growth through dietary valine restriction or inhibitors.

This study identifies ERAD activity as a predictive and heritable marker of hematopoietic stem cell function by linking cytokine signaling to proteostasis remodeling.

In THP-1 cells, hypoxia drives Lyn-dependent YY1 phosphorylation and phase separation; YY1 and NUSAP1 SUMOylate and stabilize HIF-1α, and degrading YY1 curbs mouse prostate tumors.

This study identifies a hypoxic eIF1A+ luminal cell cluster in prostate cancer that promotes tumor progression and creates an immunosuppressive microenvironment, with potential therapeutic implications.

This study identifies METTL3-mediated stabilization of RRBP1 mRNA via m6A in prostate cancer and develops small-peptide inhibitors to target this pathway.

This study characterizes integrin family alterations across 32 cancer types, identifies integrinScore as a prognostic marker, and proposes potential therapeutic targets.

This paper develops a stapled peptide inhibitor of METTL3-METTL14 that suppresses tumor growth by inhibiting m6A methylation and promoting METTL3 degradation.

The paper identifies intron retention as a hallmark of aggressive prostate cancer and highlights the spliceosome as a therapeutic target by analyzing splicing dysregulation across prostate cancer progression.